(Adds further details, context)
April 9 (Reuters) - Australia's CSL Ltd (CSL) on Thursday reaffirmed profit guidance for full year but said it expects delays in capital projects and clinical trials amid the coronavirus pandemic.
The biotechnology company reaffirmed its profit guidance range of about $2.11 billion to $2.17 billion for the 2020 fiscal year.
The Melbourne-based firm said that at present there was no interruption to its supply chain and that its facility in Wuhan, China had resumed operations.
While other Australian businesses faced a drop in sales as global movement restrictions hinder operations, CSL said demand had risen for its intravenous immunoglobulin and influenza vaccines.
Separately on Wednesday, the company's unit CSL Behring and SAB Biotherapeutics announced a partnership to develop a therapeutic to "combat the coronavirus pandemic."
News: CSL UPDATE 1-Australia's CSL Ltd reaffirms FY profit guidance amid coronavirus pandemic
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$276.86 |
Change
1.355(0.49%) |
Mkt cap ! $133.8B | |||
| Open | High | Low | Value | Volume |
| $277.50 | $278.05 | $276.45 | $29.56M | 106.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 42 | $276.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $276.86 | 11 | 4 |
View Market Depth
| Last trade - 10.56am 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$277.07 |
Change
1.355 ( 0.57 %) |
||||
| Open | High | Low | Volume | ||
| $277.13 | $278.05 | $276.45 | 7396 | ||
| Last updated 11.13am 07/05/2024 ? | |||||
| CSL (ASX) Chart |